These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37827559)

  • 1. Pathophysiological insights into machine learning-based subphenotypes of acute heart failure with preserved ejection fraction.
    Sotomi Y; Tamaki S; Hikoso S; Nakatani D; Okada K; Dohi T; Sunaga A; Kida H; Sato T; Matsuoka Y; Sakamoto D; Kitamura T; Komukai S; Seo M; Yano M; Hayashi T; Nakagawa A; Nakagawa Y; Ohtani T; Yasumura Y; Yamada T; Sakata Y;
    Heart; 2024 Feb; 110(6):441-447. PubMed ID: 37827559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
    Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
    ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction.
    Yin D; Yan X; Bai X; Tian A; Gao Y; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1025-1034. PubMed ID: 36519216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
    Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
    Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction.
    Sabbah MS; Fayyaz AU; de Denus S; Felker GM; Borlaug BA; Dasari S; Carter RE; Redfield MM
    Circ Heart Fail; 2020 Aug; 13(8):e006414. PubMed ID: 32809874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
    Rabkin SW; Tang JKK
    Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model.
    Sotomi Y; Hikoso S; Nakatani D; Okada K; Dohi T; Sunaga A; Kida H; Sato T; Matsuoka Y; Kitamura T; Komukai S; Seo M; Yano M; Hayashi T; Nakagawa A; Nakagawa Y; Tamaki S; Ohtani T; Yasumura Y; Yamada T; Sakata Y;
    Heart; 2023 Jul; 109(16):1231-1240. PubMed ID: 36822821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study.
    Linde C; Ekström M; Eriksson MJ; Maret E; Wallén H; Lyngå P; Wedén U; Cabrera C; Löfström U; Stenudd J; Lund LH; Persson B; Persson H; Hage C;
    ESC Heart Fail; 2022 Aug; 9(4):2125-2138. PubMed ID: 35403374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
    Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W
    Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 20. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.